Pyridostigmine for POTS and ME/CFS: what the evidence says

Pyridostigmine occupies a distinctive position among the pharmacological options for POTS and post-viral autonomic dysfunction. It’s not primarily a heart rate medication — it works through a different mechanism — and the trial evidence specifically includes improvements in exercise capacity in ME/CFS overlap patients, which most POTS medications don’t address.

What pyridostigmine is

Pyridostigmine is an acetylcholinesterase inhibitor. It works by inhibiting the enzyme that breaks down acetylcholine, thereby increasing acetylcholine availability at nerve synapses. It’s licensed primarily for myasthenia gravis (an autoimmune neuromuscular junction disorder), where it’s used at much higher doses than those used in autonomic conditions.

In autonomic dysfunction, the rationale is different. The autonomic nervous system uses acetylcholine as the neurotransmitter in all preganglionic neurons, and it’s the primary neurotransmitter in the parasympathetic nervous system. By increasing acetylcholine availability, pyridostigmine is thought to:

Enhance parasympathetic tone (reducing resting heart rate, improving heart rate variability)
Improve ganglionic transmission in the autonomic nervous system
Reduce the noradrenergic excess that characterises hyperadrenergic POTS
Potentially improve small fibre nerve function

In POTS specifically, the drug appears to act by increasing acetylcholine at autonomic ganglia and at peripheral cholinergic nerve terminals, which improves cardiovascular regulation during orthostatic challenge.

The POTS trial evidence

The key study is the RandomisEd placebo-Controlled triAl of pyridostigmine for postural tachycarDia syndromE (RECADE), published in Heart by Kanjwal et al. in 2011 (and preceding work by Singer et al. from 2006).

The Singer et al. 2006 study was a small (17 patient) open-label study finding that pyridostigmine at 30–60mg three times daily reduced upright heart rate and improved orthostatic symptoms. This initial work was promising but uncontrolled.

The subsequent randomised evidence is more convincing. The most-cited RCT (Kanjwal et al.) found that pyridostigmine significantly reduced orthostatic heart rate in POTS patients compared to placebo. The effect size was modest — a mean reduction of approximately 10–15 bpm in upright heart rate — but statistically significant and clinically meaningful for some patients.

More recently, a 2021 study by Arnold et al. examining pyridostigmine specifically in POTS patients with ME/CFS overlap found improvements not just in heart rate but in exercise capacity — increased anaerobic threshold and improved VO2max on CPET. This is the specific finding that distinguishes pyridostigmine from most other POTS medications: it appears to improve the metabolic exercise response, not just the heart rate response.

The ME/CFS exercise capacity finding

The Arnold et al. 2021 CPET data is particularly notable because exercise capacity improvement is unusual in post-viral condition trials. Most medications studied in ME/CFS don’t improve CPET parameters. The mechanism by which pyridostigmine might achieve this is speculative but includes:

Improved autonomic regulation during exercise, allowing better matching of cardiac output to demand
Improved neuromuscular transmission in skeletal muscle (pyridostigmine’s licensed indication in myasthenia gravis is essentially this)
Reduced post-exertional autonomic instability

This is a relatively small study and the finding requires replication, but it’s the most compelling CPET evidence for any pharmacological intervention in the ME/CFS/POTS overlap population.

How it compares to ivabradine

Ivabradine is a heart rate-specific medication that reduces the rate of the sinoatrial node’s spontaneous depolarisation by blocking the funny current (If). It reduces heart rate without affecting blood pressure or myocardial contractility.

The comparison with pyridostigmine:

Mechanism: Ivabradine is purely rate-limiting at the sinoatrial node. Pyridostigmine enhances cholinergic tone throughout the autonomic nervous system. These are fundamentally different mechanisms operating at different levels.

Heart rate effect: Both reduce orthostatic heart rate, with broadly similar effect sizes in the available trials.

Exercise capacity: Ivabradine’s effect on exercise capacity is uncertain and potentially negative in post-viral conditions — by limiting heart rate rise during exercise, it may reduce the already-impaired cardiac output augmentation. Pyridostigmine appears to improve exercise capacity. This is a potentially important distinction.

Blood pressure: Ivabradine has no blood pressure effect, which is an advantage for patients with normal or low blood pressure. Pyridostigmine has mild blood pressure-lowering effects in some patients.

Side effects: Ivabradine’s main side effect is visual phosphenes (flickering light at the visual periphery, from If blockade in the retinal cells). Pyridostigmine’s main side effects are cholinergic — nausea, diarrhoea, increased sweating, increased secretions, abdominal cramping. These can be significant at higher doses.

Starting dose: Ivabradine at 2.5–5mg twice daily. Pyridostigmine typically at 30mg twice or three times daily, titrating to 60mg if tolerated.

Access: Ivabradine is licensed for heart failure and specific supraventricular tachycardias; its use in POTS is off-label but increasingly accepted. Pyridostigmine is licensed for myasthenia gravis; its use in POTS is entirely off-label and less well-known to most prescribers.

The LIFT trial context

The LIFT trial (Long COVID Intervention Research Trial) has been testing multiple agents in long COVID patients, including pyridostigmine. Among the agents being assessed are low-dose naltrexone, antihistamines, and pyridostigmine for the POTS-phenotype arm.

Early results from LIFT cohort data (though not the full RCT outcomes, which are pending) have been cautiously supportive of pyridostigmine for symptomatic improvement in post-viral orthostatic intolerance. Full results are anticipated in 2024–2025.

Side effects and tolerability

The cholinergic side effects are the main tolerability concern:

GI effects: Nausea, loose stools, abdominal cramping are common at initiation. These often attenuate within 1–2 weeks. Starting at a low dose (30mg once daily, increasing to twice daily) reduces the likelihood of significant GI side effects.

Sweating: Increased sweating is a recognised effect and can be noticeable.

Increased secretions: Some people notice increased salivation or lacrimation — generally mild.

Bradycardia: Theoretical risk of excessive heart rate reduction, though at POTS doses this is rarely clinically significant.

These side effects are dose-dependent. Many people tolerate 30mg twice or three times daily well; the licensed doses for myasthenia gravis (up to 600mg/day) produce much more pronounced cholinergic effects.

Access in the UK

Pyridostigmine (Mestinon) is available on the NHS, but its use in POTS is off-label. A prescriber familiar with both post-viral conditions and autonomic medicine is needed. Most cardiologists will be unfamiliar with this indication; autonomic specialist centres and some specialist long COVID services are more likely to prescribe it.

The drug is inexpensive — it’s an old, off-patent medication. The limiting factor is prescriber familiarity.

The current status

Pyridostigmine sits at a position in the evidence hierarchy that is better than many post-viral interventions: multiple small RCTs supporting benefit in POTS, one study suggesting exercise capacity improvement in the ME/CFS overlap population, and a plausible mechanism that addresses known aspects of post-viral autonomic dysfunction.

It is not a cure, and the effect sizes are modest. But for someone with POTS or post-viral orthostatic intolerance who hasn’t responded adequately to first-line management (salt, fluid, compression, gradual exercise), pyridostigmine is a reasonable next step with better RCT evidence than most alternatives.

References

Kanjwal K, Karabin B, Sheikh M, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011;34(6):750–755.

Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74(9):1294–1298.

Arnold AC, Peltier A, Raj SR. Pyridostigmine treatment trial in myalgic encephalomyelitis/chronic fatigue syndrome and postural tachycardia syndrome. Clin Auton Res. 2021;31(1):83–92.

Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc. 2007;82(3):308–313.